Gilead’s clinical development program is growing, and we are proud to announce the addition of early pipeline assets in oncology and inflammation. https://t.co/XSvUgka7qy
We are pleased to announce new positive interim results from a Phase 3 study investigating our treatment in patients with HR+/HER2- metastatic breast cancer. Learn more. https://t.co/hxzkBNEync
Today we announced an agreement with Everest Medicines to transfer all development and commercialization rights to Gilead for one of our cancer therapies in Asia. Learn more. https://t.co/ebWyzXJgVS
Today, the @US_FDA has approved our medicine for the treatment of adult patients with plaque psoriasis regardless of disease severity, for the 8 million Americans affected by this disease. $AMGN
New 2020 @SanofiUS#drug pricing:
List prices: +0.2%
Net prices: -7.8%
1) Massive #GrossToNetBubble
2) 5th year of net price declines 👇
3) #Rebates = 54% (!) of gross sales
Sadly, drug pricing flat earthers #DPFE will ignore these data
https://t.co/TRUcvgrJei
My group at @Amgen is expanding! Come join the Induced Proximity Platform for Targeted Protein and RNA Degradation #PROTACs#GLUEs. I'm recruiting 3 GROUP LEADERS! Great opportunity to break into this exciting field. More info below. 👇 Please RT
2020 has been a year marked by challenges, but also a year of incredible progress. We're proud to reflect on some of our top #AmgenScience moments as we continue to work towards a better tomorrow.
🚨GIVEAWAY TIME🚨
I’m giving my ORIGINAL painting away...to enter: simply retweet this post and your in
WINNER PICKED MONDAY!
I knew when I woke up today I had to paint our beloved RBG...our QUEEN
So I did just that this afternoon
I want someone to have it...
#RIPRBG
Know AML is proud to be supported by the following organizations. Thank you AbbVie, Amgen, Astellas, Bristol Myers Squibb, Jazz, Agios, Daiichi Sankyo and Novartis ❤️🖤#KnowAML#leusm#BloodCancer